Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444986 | 0.95 | HTT (0.67) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL7283765 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL7285301 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL7283534 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL3151115 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL7283930 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL9222029 | 0.94 | TGM2 (0.65) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL6539554 | 0.91 | LMNA (0.67) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL7855188 | 0.89 | HTT (0.70) | HTTLMNASMN1; SMN2KEAP1NFE2L2 | |
| SCHEMBL18254066 | 0.87 | HTT (0.81) | HTTLMNASMN1; SMN2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | claimed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | claimed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | claimed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-4851387-A | RENIN INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0272583-A2 | 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | HTT 969/4885LMNA 2061/4885SMN1; SMN2 1678/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | HTT 1006/4885LMNA 136/4885SMN1; SMN2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.